Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581982 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
A Phase 2 study of Transitional Cell Carcinoma, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT02581982 is a Phase 2 study of Transitional Cell Carcinoma that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 27 participants, below the 179-participant average among 4 other Transitional Cell Carcinoma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02581982, a Phase 2 study of Transitional Cell Carcinoma, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well paclitaxel and pembrolizumab works in treating patients with urothelial cancer that has not responded to previous treatment and has spread to other places in the body. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving paclitaxel together with pembrolizumab may be an effective treatment for urothelial cancer.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Laboratory Biomarker Analysis
- DRUG Paclitaxel
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-04-06 |
| Est. Completion | 2022-12-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02581982
The ClinicalTrials.gov registry entry for NCT02581982 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 4 other Transitional Cell Carcinoma trials with a reported enrollment target (85% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transitional Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT02581982 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02581982 about?
NCT02581982 is a clinical study titled "Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer". This phase II trial studies how well paclitaxel and pembrolizumab works in treating patients with urothelial cancer that has not responded to previous treatment and has spread to other places in the body. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tu...
What is the current status of trial NCT02581982?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2016-04-06. Estimated completion is 2022-12-19.
What conditions does trial NCT02581982 study?
This clinical trial studies the following conditions: Transitional Cell Carcinoma.
What interventions are being tested in trial NCT02581982?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02581982?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02581982 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transitional Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
COMPLETED · Phase 2
-
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
COMPLETED · Phase 2
-
Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 1
-
Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.